[go: up one dir, main page]

WO2003020723A1 - Derive de [1,2,4]triazolo[1,5-a]pyrimidine - Google Patents

Derive de [1,2,4]triazolo[1,5-a]pyrimidine Download PDF

Info

Publication number
WO2003020723A1
WO2003020723A1 PCT/JP2002/008666 JP0208666W WO03020723A1 WO 2003020723 A1 WO2003020723 A1 WO 2003020723A1 JP 0208666 W JP0208666 W JP 0208666W WO 03020723 A1 WO03020723 A1 WO 03020723A1
Authority
WO
WIPO (PCT)
Prior art keywords
triazolo
pyrimidine derivative
adenosine
receptor
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008666
Other languages
English (en)
Japanese (ja)
Inventor
Hitoshi Arai
Daisuke Machii
Koji Hagihara
Michio Ichimura
Junichi Enokizono
Shizuo Shiozaki
Junichi Shimada
Koji Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to JP2003524993A priority Critical patent/JPWO2003020723A1/ja
Publication of WO2003020723A1 publication Critical patent/WO2003020723A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un dérivé de [1,2,4]triazolo[1,5-a]pyrimidine de formule (I), dans laquelle Y représente hydrogène ou un alkyle inférieur (non) substitué; Z représente oxygène ou soufre; et X représente (II) ou (III), ou un sel pharmaceutiquement acceptable de ce dérivé. Ces dérivés présentent une activité antagoniste dirigée contre un récepteur A2A de l'adénosine, et sont utiles pour des traitements et/ou une prévention de maladies variées, attribuables à l'hyperénergie d'un récepteur A2A de l'adénosine, par exemple le parkinsonisme.
PCT/JP2002/008666 2001-08-30 2002-08-28 Derive de [1,2,4]triazolo[1,5-a]pyrimidine Ceased WO2003020723A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003524993A JPWO2003020723A1 (ja) 2001-08-30 2002-08-28 ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-262095 2001-08-30
JP2001262095 2001-08-30

Publications (1)

Publication Number Publication Date
WO2003020723A1 true WO2003020723A1 (fr) 2003-03-13

Family

ID=19089037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008666 Ceased WO2003020723A1 (fr) 2001-08-30 2002-08-28 Derive de [1,2,4]triazolo[1,5-a]pyrimidine

Country Status (2)

Country Link
JP (1) JPWO2003020723A1 (fr)
WO (1) WO2003020723A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099776A1 (fr) * 2002-05-23 2003-12-04 Amgen Inc. Arylalkylamines modulant un recepteur calcique
WO2004092177A1 (fr) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
JP2012520854A (ja) * 2009-03-20 2012-09-10 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ アデノシンａ２ａ受容体のリガンドとして有用なトリアゾリルプリンの酸化誘導体とその薬剤としての使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0499775A (ja) * 1990-08-20 1992-03-31 Dai Ichi Seiyaku Co Ltd ２位置換トリアゾロピリミジン類
WO1999043678A1 (fr) * 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0499775A (ja) * 1990-08-20 1992-03-31 Dai Ichi Seiyaku Co Ltd ２位置換トリアゾロピリミジン類
WO1999043678A1 (fr) * 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Medicaments et prophylaxie contre la maladie de parkinson

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099776A1 (fr) * 2002-05-23 2003-12-04 Amgen Inc. Arylalkylamines modulant un recepteur calcique
AU2003233671B8 (en) * 2002-05-23 2003-12-12 Amgen Inc. Calcium receptor modulating arylalkylamines
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7196102B2 (en) 2002-05-23 2007-03-27 Amgen Inc. Calcium receptor modulating agents
AU2003233671B2 (en) * 2002-05-23 2007-08-16 Amgen Inc. Calcium receptor modulating arylalkylamines
JP2010150268A (ja) * 2002-05-23 2010-07-08 Amgen カルシウム受容体調節剤
WO2004092177A1 (fr) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines et procedes de preparation et d'utilisation ce celles-ci
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
JP2012520854A (ja) * 2009-03-20 2012-09-10 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ アデノシンａ２ａ受容体のリガンドとして有用なトリアゾリルプリンの酸化誘導体とその薬剤としての使用

Also Published As

Publication number Publication date
JPWO2003020723A1 (ja) 2004-12-16

Similar Documents

Publication Publication Date Title
EP1505068A4 (fr) DERIVE DE PYRAZOLO(1,5-a)PYRIMIDINE ET INHIBITEUR DE LA NAD(P)H OXYDASE CONTENANT LEDIT DERIVE
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
WO2003035639A1 (fr) Compose de pyrimidine et composition medicinale contenant ledit compose
CY1105553T1 (el) Υποκαταστατα 2-πυριμιδινυλιο-6,7,8,9-τετραϋδροπυριμιδο[1,2-α]πυριμιδιν-4-ονιο και 7-πυριμιδινυλιο-2,3-διυδροιμιδαζο[1,2-α]πυριμιδιν-5(1η)ονιο για νευροεκφυλιστικες διαταραχες
WO2005049616A8 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines a effet inhibiteur par rapport a la pde-5
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
DK1401837T3 (da) Purinderivater som A2B-adenosinreceptorantagonister
WO2003022216A3 (fr) Derives de purine a substitution biaryle utilises comme agents antiproliferatifs puissants
MY126736A (en) 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
EP2078721A3 (fr) Composés thiéno-pyrimidines ayant une activité fongicide
NO20055510L (no) 2-alkynyl- og 2-alkenylpyrazolo [4,3-E]-1,2,4-triazolo-[1,5-C]-pyrimidin-adenosin A2A-reseptorantagonister
EP1477490A4 (fr) Derive pyrrolopyrimidine
WO2003022805A3 (fr) Derives de purine a substitution heterocycle utiles en tant que puissants agents antiproliferatifs
TR200402342T4 (tr) 2-Pirindinil-6,7,8,9- Tetrahidropyrimido[1,2-A] Pirimidin-4-On ve 7-Pirindinil-1,3-Dihydoimidazo[1,2-A]Pirimidin-5(1H) on Türevleri
WO2003022219A3 (fr) Derives de purine biaryle a substitution azote utiles en tant que puissants agents antiproliferatifs
WO2003068776A1 (fr) Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
TWI349674B (en) Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof
EP2258372B8 (fr) L'utilisation des antagonistes des récepteurs A2A pour le treaitment de troubles de motricité
WO2003008365A3 (fr) Derives de phenylacetamido-thiazole, leur procede de preparation et leur utilisation en tant qu'agents antitumoraux
WO2004106339A3 (fr) Derives substitues en 4 de pyrazolo[3,4-d]pyrimidine et de pyrrolo[2,3-d]pyrimidine et leurs utilisations
WO2004092171A3 (fr) Triazolo[1,5-a]pyrimidines et pyrazolo[1,5-a]pyrimidines et procedes de preparation et d'utilisation de celles-ci
WO2003059878A3 (fr) Composes antiviraux
MXPA03003923A (es) Compuestos de n-([1,2,4]triazoloazinil)tiofensulfonamida como herbicidas.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003524993

Country of ref document: JP

122 Ep: pct application non-entry in european phase